

# Review of: "TROPION-Lung01 Results Indicate PFS Benefit With Datopotamab Deruxtecan Over Docetaxel in Previously Treated Nonsquamous NSCLC: A Critique and a Question"

Wolf-Dieter Janthur<sup>1</sup>

<sup>1</sup> oncology, Kantonsspital Aarau AG, Aarau, Switzerland

Potential competing interests: No potential competing interests to declare.

Dear author,

In general, I consider the issue of spinning study results as important and of high value. Your work sensitizes consumers and raises awareness among oncologists to respect all aspects of such trials, especially with tight results and thin benefits that only apply to subgroups. So I congratulate you for choosing such an exciting and conflicting theme.

You could even be a little more straightforward and provocative, but you should also explain the term CONSORT and its evaluation algorithm.

Your explanation of the study results seems fair and appropriate, as does your conclusion.

Also, presenting studies alike to underline the phenomena of spinning could have been helpful to avoid underrating the issue, but after all, I am satisfied being confronted with your text.

Parts that could use modification:

"binary data (progression-free / progression, (alive/death) as per CONSORT guidelines" (erase the bracket before alive)

"we emphasize the need for further research to develop a framework of how oncologists might explain the differences between PFS and OS in simple terms for a lay audience to improve a more informed decision of patients to embark on any cancer treatment" (complicated, especially "improve a more decision", better help to create a more thoughtful decision)

"What would a presentation of absolute risks influence the study's conclusions?" (it must say "how" would a presentation....)

"no statistically significant changes in absolute risks for progression of death were observed, but a risk increase for progression in the patients with squamous histology." (not progression OF death, better progression or death)

"of results presentation in RCTs" (better presentation of results)

Good luck, kind regards, and all the best,



Wolf-Dieter Janthur